Edition:
United Kingdom

Bayer AG (BAYGn.DE)

BAYGn.DE on Xetra

69.27EUR
4:35pm BST
Change (% chg)

€-7.27 (-9.50%)
Prev Close
€76.54
Open
€70.21
Day's High
€71.70
Day's Low
€67.07
Volume
11,459,452
Avg. Vol
3,667,969
52-wk High
€116.37
52-wk Low
€67.07

Latest Key Developments (Source: Significant Developments)

Sanofi to launch new Primary Care and China/Emerging Market business units
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - Sanofi SA ::* To refocus two global business units (GBU).* Will create new Primary Care GBU that combines the product portfolios of Sanofi's existing Diabetes and Cardiovascular (DCV) GBU with Established Products, which are currently part of the General Medicines & Emerging Markets (GEM) GBU.* Creating a second new global business unit called China & Emerging Markets to be led by Olivier Charmeil, currently head of the GEM GBU..* Dieter Weinand to lead new Primary Care business unit.* Stefan Oelrich, currently head of the DCV GBU, has decided to leave Sanofi and will join Bayer AG .* Sanofi expects to launch the new Primary Care and China & Emerging Markets global business units by the beginning of 2019.  Full Article

Bayer Says Stefan Oelrich To Join Board Of Management And Head Pharmaceuticals Division
Thursday, 13 Sep 2018 

Sept 13 (Reuters) - Bayer AG ::STEFAN OELRICH TO JOIN BAYER BOARD OF MANAGEMENT AND HEAD PHARMACEUTICALS DIVISION.DIETER WEINAND LEAVING THE COMPANY AS OF NOVEMBER 1, 2018.EXTENSIONS FOR BOARD OF MANAGEMENT MEMBERS LIAM CONDON AND DR. HARTMUT KLUSIK.DIETER WEINAND IS LEAVING THE COMPANY.  Full Article

Bayer Says Conditions For Beginning Monsanto Integration Fulfilled
Thursday, 16 Aug 2018 

Aug 16 (Reuters) - Bayer Ag ::CONDITIONS FOR BEGINNING MONSANTO INTEGRATION FULFILLED.COMPLETION OF DIVESTMENT OF CERTAIN CROP SCIENCE BUSINESSES WITH TOTAL SALES VOLUME OF AROUND 2.2 BILLION EUROS.COMMENTS ON GLYPHOSATE VERDICT IN CALIFORNIA ON AUGUST 10, 2018.BELIEVES COURTS ULTIMATELY WILL FIND THAT MONSANTO AND GLYPHOSATE WERE NOT RESPONSIBLE FOR PROSECUTING PARTY'S ILLNESS.BELIEVES JURY’S DECISION IS AT ODDS WITH WEIGHT OF SCIENTIFIC EVIDENCE, WORLD EXPERIENCE AND CONCLUSIONS OF REGULATORS AROUND WORLD.  Full Article

BASF says closes acquisition of vegetable seeds business from Bayer
Thursday, 16 Aug 2018 

Aug 16 (Reuters) - BASF SE ::SAYS CLOSES ACQUISITION OF VEGETABLE SEEDS BUSINESS FROM BAYER.  Full Article

AMVAC Chemical Acquires Bromacil Herbicide Business Assets From Bayer Crop Science
Thursday, 21 Jun 2018 

June 21 (Reuters) - American Vanguard Corp ::AMVAC CHEMICAL ACQUIRES BROMACIL HERBICIDE BUSINESS ASSETS FROM BAYER CROP SCIENCE.AMERICAN VANGUARD CORP - TRANSACTION IS UNRELATED TO ACQUISITION OF MONSANTO BY BAYER.AMERICAN VANGUARD CORP - FINANCIAL TERMS OF AGREEMENT WERE NOT DISCLOSED.AMERICAN VANGUARD CORP - BAYER CROP SCIENCE WILL CONTINUE TO MARKET AND PROVIDE CUSTOMER SUPPORT FOR HYVAR AND KROVAR UNTIL END OF SEPTEMBER 2018.  Full Article

Bayer Says U.S. FDA Accepts Larotrectinib New Drug Application
Tuesday, 29 May 2018 

May 29 (Reuters) - Bayer ::SAYS U.S. FDA ACCEPTS LAROTRECTINIB NEW DRUG APPLICATION AND GRANTS PRIORITY REVIEW.SAYS U.S. FDA GRANTED PRIORITY REVIEW FOR LAROTRECTINIB FOR THE TREATMENT OF ADULT AND PEDIATRIC PATIENTS.  Full Article

FDA Accepts Larotrectinib New Drug Application And Grants Priority Review
Tuesday, 29 May 2018 

May 29 (Reuters) - Loxo Oncology Inc ::FDA ACCEPTS LAROTRECTINIB NEW DRUG APPLICATION AND GRANTS PRIORITY REVIEW.LOXO ONCOLOGY INC - PDUFA DATE SET FOR NOVEMBER 26, 2018 FOR LAROTRECTINIB.LOXO ONCOLOGY INC - LAROTRECTINIB HAS ALSO BEEN GRANTED BREAKTHROUGH THERAPY DESIGNATION.LOXO ONCOLOGY INC - BAYER PLANS TO SUBMIT A MARKETING AUTHORIZATION APPLICATION (MAA) IN EUROPEAN UNION IN 2018.  Full Article

FDA Says Making List Of Cos Blocking Access To Samples Of Branded Products
Thursday, 17 May 2018 

May 17 (Reuters) - FDA::FDA COMMISSIONER SCOTT GOTTLIEB SAYS MAKING PUBLIC LIST OF COS THAT HAVE POTENTIALLY BEEN BLOCKING ACCESS TO THE SAMPLES OF THEIR BRANDED PRODUCTS.FDA'S GOTTLIEB - ALSO NOTIFYING FEDERAL TRADE COMMISSION ABOUT INQUIRIES RECEIVED FROM GENERIC DRUG DEVELOPERS.FDA'S GOTTLIEB - FDA WILL DETERMINE WHETHER THE PRODUCTS HAVE IN PLACE RISK EVALUATION & MITIGATION STRATEGY PROGRAM WITH ETASU THAT MAY IMPACT DISTRIBUTION.FDA'S GOTTLIEB SAYS IN MANY CASES, WE FIND THAT THERE’S NO SUCH REMS PROGRAM IN PLACE.FDA'S GOTTLIEB - COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE NOVARTIS PHARMA, ACTELION PHARMA, VALEANT, SMITHKLINE BEECHAM, GILEAD, CELGENE.FDA'S GOTTLIEB - COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE BIOGEN IDEC, INSYS THERAPEUTICS, LUNDBECK LLC, HYPERION THERAPEUTICS, VIVUS INC.FDA'S GOTTLIEB - COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE PFIZER PHARMACEUTICALS PRODUCTION, SWEDISH ORPHAN BIOVITRUM, MEDA PHARMA.FDA'S GOTTLIEB - COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE DANCO LABORATORIES, ROXANE LABORATORIES, CORCEPT THERAPEUTICS, AEGERION PHARMA.FDA'S GOTTLIEB - COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE PHARMACIA AND UPJOHN CO, QUESTCOR PHARMACEUTICALS, BOEHRINGER INGELHEIM, NPS PHARMA.FDA'S GOTTLIEB - COS FOR WHICH INQUIRIES HAVE BEEN RECEIVED INCLUDE SHIRE ORPHAN THERAPIES, APOPHARMA, CEPHALON INC, JAZZ PHARMA, CUBIST PHARMA.  Full Article

Bayer Receives Approval For Eylea In China
Friday, 11 May 2018 

May 11 (Reuters) - Bayer AG ::SAYS RECEIVES APPROVAL FOR EYLEA IN CHINA.EYLEA GAINS APPROVAL IN CHINA FOR TREATMENT OF VISUAL IMPAIRMENT DUE TO NEOVASCULAR (WET) AGE-RELATED MACULAR DEGENERATION.  Full Article

Bayer Announces Executive Leadership Team For New Crop Science Division
Monday, 7 May 2018 

May 7 (Reuters) - BAYER AG ::ANNOUNCES EXECUTIVE LEADERSHIP TEAM FOR NEW CROP SCIENCE DIVISION.NEW EXECUTIVE LEADERSHIP TEAM WILL BE LED BY LIAM CONDON.  Full Article

UPDATE 2-European shares march towards 2 year lows as earnings, politics weigh

* Earnings fail to offset political worries (Adds details, closing prices)